TY - JOUR
T1 - The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis
T2 - Results of an italian multicentre study
AU - Quartuccio, Luca
AU - Fabris, Martina
AU - Pontarini, Elena
AU - Salvin, Sara
AU - Zabotti, Alen
AU - Benucci, Maurizio
AU - Manfredi, Mariangela
AU - Biasi, Domenico
AU - Ravagnani, Viviana
AU - Atzeni, Fabiola
AU - Sarzi-Puttini, Piercarlo
AU - Morassi, Pia
AU - Fischetti, Fabio
AU - Tomietto, Paola
AU - Bazzichi, Laura
AU - Saracco, Marta
AU - Pellerito, Raffaele
AU - Cimmino, Marco
AU - Schiavon, Franco
AU - Carraro, Valeria
AU - Semeraro, Angelo
AU - Caporali, Roberto
AU - Cavagna, Lorenzo
AU - Bortolotti, Roberto
AU - Paolazzi, Giuseppe
AU - Govoni, Marcello
AU - Bombardieri, Stefano
AU - De Vita, Salvatore
PY - 2014
Y1 - 2014
N2 - Objective: The polymorphism 158V/F of Fc fragment of IgG (FCGR) type 3A may influence the response to rituximab (RTX) in rheumatoid arthritis (RA). We investigated the FCG3A polymorphism in a large cohort of RA patients treated with RTX, also by considering the possible loss of response from month +4 to +6 after RTX and the presence of established predictors of response. Methods: The study analysed 212 RA patients. European League Against Rheumatism (EULAR) response was evaluated at months +4 and +6 after the first RTX infusion. The FCGR3A polymorphism was analysed by PCR followed by Sanger sequencing. Results: The FCGR3A genotypes were associated with EULAR response (good or moderate) at month +6 (response in 34/38 (89.5%) VV vs 70/106 (66%) VF and in 51/77 (66.2%) FF patients; p=0.01), but not at month +4 (response in 32/37 (86.5%) VV vs 69/102 (67.6%) VF and 53/73 (72.6%) FF patients; p=0.09). Loss of response was observed only in VF and FF carriers ((VV vs VF vs FF: 0/37 (0%) vs 11/102 (10.8%) vs 12/73 (16.4%); p=0.02)). Probability of response at month +6 was very high when at least two of the three following items selected by multivariate analysis were present: positive rheumatoid factor and/or anticyclic citrullinated peptide antibodies, previous treatment with ≤1 anti-tumor necrosis factor (TNF) agent, and 158VV FCGR3A genotype (p
AB - Objective: The polymorphism 158V/F of Fc fragment of IgG (FCGR) type 3A may influence the response to rituximab (RTX) in rheumatoid arthritis (RA). We investigated the FCG3A polymorphism in a large cohort of RA patients treated with RTX, also by considering the possible loss of response from month +4 to +6 after RTX and the presence of established predictors of response. Methods: The study analysed 212 RA patients. European League Against Rheumatism (EULAR) response was evaluated at months +4 and +6 after the first RTX infusion. The FCGR3A polymorphism was analysed by PCR followed by Sanger sequencing. Results: The FCGR3A genotypes were associated with EULAR response (good or moderate) at month +6 (response in 34/38 (89.5%) VV vs 70/106 (66%) VF and in 51/77 (66.2%) FF patients; p=0.01), but not at month +4 (response in 32/37 (86.5%) VV vs 69/102 (67.6%) VF and 53/73 (72.6%) FF patients; p=0.09). Loss of response was observed only in VF and FF carriers ((VV vs VF vs FF: 0/37 (0%) vs 11/102 (10.8%) vs 12/73 (16.4%); p=0.02)). Probability of response at month +6 was very high when at least two of the three following items selected by multivariate analysis were present: positive rheumatoid factor and/or anticyclic citrullinated peptide antibodies, previous treatment with ≤1 anti-tumor necrosis factor (TNF) agent, and 158VV FCGR3A genotype (p
UR - http://www.scopus.com/inward/record.url?scp=84895448860&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84895448860&partnerID=8YFLogxK
U2 - 10.1136/annrheumdis-2012-202435
DO - 10.1136/annrheumdis-2012-202435
M3 - Article
C2 - 23505228
AN - SCOPUS:84895448860
VL - 73
SP - 716
EP - 721
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
SN - 0003-4967
IS - 4
ER -